Trial Profile
Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy Subjects
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 21 Oct 2016
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary) ; Rifampicin (Primary)
- Indications Tuberculosis; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 22 Mar 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
- 06 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Sep 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.